Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock, $0.00000002 par value
-
Shares outstanding
-
29.5M
-
Number of holders
-
45
-
Total 13F shares, excl. options
-
48.8M
-
Shares change
-
-3.29M
-
Total reported value, excl. options
-
$11.2M
-
Value change
-
-$894K
-
Put/Call ratio
-
0.12
-
Number of buys
-
14
-
Number of sells
-
-16
-
Price
-
$0.23
Significant Holders of MEI Pharma, Inc. - Common Stock, $0.00000002 par value (MEIP) as of Q1 2023
53 filings reported holding MEIP - MEI Pharma, Inc. - Common Stock, $0.00000002 par value as of Q1 2023.
MEI Pharma, Inc. - Common Stock, $0.00000002 par value (MEIP) has 45 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.8M shares
.
Largest 10 shareholders include Anson Funds Management LP (13.3M shares), VANGUARD GROUP INC (7.67M shares), TANG CAPITAL MANAGEMENT LLC (5.16M shares), ACADIAN ASSET MANAGEMENT LLC (4.76M shares), Boxer Capital, LLC (2.91M shares), RENAISSANCE TECHNOLOGIES LLC (2.8M shares), Laurion Capital Management LP (2.58M shares), CARLSON CAPITAL L P (2.1M shares), MORGAN STANLEY (1.46M shares), and BlackRock Inc. (1.35M shares).
This table shows the top 45 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.